Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

This study is testing a combination of stem cell transplant (ASCT) and BCMA-targeting CAR-T cell therapy for patients with ultra-high-risk multiple myeloma (UHR-MM) — a particularly aggressive form of this blood cancer. The goal is to see if this intensive combination can achieve better and longer-lasting responses. **You may be eligible if:** - You are between 18 and 70 years old and fit enough for a stem cell transplant - You have ultra-high-risk multiple myeloma, defined by specific high-risk genetic features (such as del(17p), TP53 mutation, or multiple cytogenetic abnormalities), primary refractory disease, or early progression after initial treatment - Your cancer has measurable disease by standard lab tests **You may NOT be eligible if:** - You do not meet the definition of ultra-high-risk multiple myeloma - You are not healthy enough for a stem cell transplant - Your organ function does not meet requirements Talk to your doctor to see if this trial is right for you.